Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported first quarter EPS of $-0.120, $0.02 better than the analyst estimate of $-0.140. Revenue for the quarter came in at $1.46M versus the consensus estimate of $4.09M.
Aclaris Therapeutics Inc’s stock price closed at $1.31. It is down -47.390% in the last 3 months and up 6.940% in the last 12 months.
Aclaris Therapeutics Inc saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Aclaris Therapeutics Inc’s stock price’s past reactions to earnings here.
According to InvestingPro, Aclaris Therapeutics Inc’s Financial Health score is "fair performance".
Check out Aclaris Therapeutics Inc’s recent earnings performance, and Aclaris Therapeutics Inc’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar